The Effect of Surgically Induced Weight Loss on Endocrine Function, Cardiovascular Function and Body Composition
Recruitment status was Active, not recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
This study is being conducted to evaluate changes in sugar, metabolism, heart function and changes in body composition as patients lose weight following bariatric surgery. The investigators will compare improvements of the above changes as a function of the four different types of bariatric surgery. The investigators believe the most beneficial and safest procedure will be the Roux-en-Y.
| Condition | Intervention | Phase |
|---|---|---|
|
Bariatric Surgery |
Drug: GLP-1 |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label |
| Official Title: | The Effect of Surgically Induced Weight Loss on Endocrine Function, Cardiovascular Function and Body Composition |
- Insulin secretion [ Time Frame: 2 years ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 70 |
| Study Start Date: | May 2007 |
| Estimated Study Completion Date: | May 2012 |
| Estimated Primary Completion Date: | October 2010 (Final data collection date for primary outcome measure) |
-
Drug: GLP-1
The study will also examine the response of the pancreas (the insulin-producing organ) to a sugar load, as well as to a hormone called GLP-1, which is released from your gut to maximally stimulate your pancreas. The release of this hormone increases when you eat food and it causes the pancreas to release more insulin than does sugar alone. Volunteers will have 22 visits over a two year period. Only people having Roux-en-Y gastric bypass surgery, gastric sleeve surgery, duodenal switch gastric surgery or lap-band/gastric banding surgery may join. Seventy volunteers will be recruited to take part in this study.
Eligibility| Ages Eligible for Study: | 21 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Male and female volunteers 21-65 years.
- BMI > 40.
- Preoperative hematocrit level of at least 34% for women and 38% for men.
- Postoperative hematocrit level of at least 34% for women and 36% for men.
Exclusion Criteria:
- Volunteers whose hematocrit level does not meet the above criteria.
- Pregnant and or lactating females.
Contacts and Locations| United States, Maryland | |
| Johns Hopkins Bayview Medical Center | |
| Baltimore, Maryland, United States, 21224 | |
| Principal Investigator: | Dariush Elahi, PhD | Johns Hopkins University |
More Information
No publications provided
| Responsible Party: | Dariush Elahi, PhD, Johns Hopkins University |
| ClinicalTrials.gov Identifier: | NCT00686972 History of Changes |
| Other Study ID Numbers: | NA_00004876 |
| Study First Received: | May 27, 2008 |
| Last Updated: | March 25, 2010 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Johns Hopkins University:
|
Bariatric Surgery Glucose Regulation Cardiac Function Body Composition |
Additional relevant MeSH terms:
|
Weight Loss Body Weight Changes Body Weight Signs and Symptoms Glucagon-Like Peptide 1 Glucagon Incretins |
Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Pharmacologic Actions Gastrointestinal Agents Therapeutic Uses |
ClinicalTrials.gov processed this record on May 23, 2013